Patients taking Novo Nordisk's obesity drug Wegovy maintained an average of 10% weight loss for up to four years, according to a new analysis from the longest clinical trial to date on the treatment.
LONDON, May 14 (Reuters) - Patients taking Novo Nordisk's (NOVOb.CO) , opens new tab Wegovy obesity treatment maintained an average of 10% weight loss after four years, potentially boosting the ...
Patients using Novo Nordisk’s NVO NONOF obesity treatment, Wegovy, have reportedly maintained an average weight loss of 10% over a four-year period, as per data revealed by the company on Tuesday.
Novo Nordisk, the pharmaceutical company behind Ozempic, has launched a national campaign promoting its injectable ...
Those with the genetic variants associated with a "hungry gut" lost an average of 14.4% of their body weight after nine months. Given Wegovy's high cost, these genetic markers could be used to ...
The study looked at whether people on Wegovy maintained their weight loss. Amid the growing popularity of drugs used for weight loss like Ozempic, Wegovy, Mounjaro and Zepbound, one question has ...
LONDON - Patients taking Novo Nordisk’s Wegovy obesity treatment maintained an average of 10 per cent weight loss after four years, potentially boosting the drugmaker’s case to insurers and ...